These are promising results
Now, faced with these results “clinically significant”, but marked with a “lack of statistical significance”, Professor Kevin Harrington, professor of biological cancer therapies at ICR, announced to our British colleagues that a “longer follow-up to see if we can demonstrate a survival benefit for all patients in the trial” would take place soon.
defends the ambition of information
verified and accessible to all thanks to the income of the
To help us maintain this free service you can “change your choice” and accept all cookies.
MODIFY AND ACCEPT ALL